Suppliers / Dr Reddys Laboratories Ltd, Unit VI

Dr Reddys Laboratories Ltd, Unit VI

India 2 duplicate records merged Updated 9 July 2026

The public registers hold a second record for Dr Reddys Laboratories Ltd, Unit VI. The fuller profile, with 279 active US DMFs and 90 valid CEPs, is at Dr Reddy's Laboratories. Figures on this page cover only this record.

Dr Reddys Laboratories Ltd, Unit VI is an API manufacturer based in India.

0
active US DMFs
0
valid CEPs
0
registered plants
0
filings across 0 regulators

What they file, and where

Molecule Regulators Docs
Cabazitaxel SFDA (Saudi Arabia) 1
Decitabine SFDA (Saudi Arabia) 1
Levetiracetam SFDA (Saudi Arabia) 1
Rivaroxaban SFDA (Saudi Arabia) 1
Ticagrelor SFDA (Saudi Arabia) 1

Also appears on these molecule pages

Cabazitaxel API Decitabine API Levetiracetam API Rivaroxaban API Ticagrelor API

Questions about Dr Reddys Laboratories Ltd, Unit VI

What does Dr Reddys Laboratories Ltd, Unit VI make?
5 molecules are on record against Dr Reddys Laboratories Ltd, Unit VI, including Cabazitaxel, Decitabine, Levetiracetam and Rivaroxaban. Each links through to that molecule's full manufacturer list.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Dr Reddys Laboratories Ltd, Unit VI comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Comparable suppliers

Abbott Healthcare also in India Accent Pharmaceuticals Diagnostics also in India Accure Labs Pvt.Ltd also in India ACME Formulation also in India Acme Generics also in India

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability